Central Pain Syndrome in Survivors of Head and Neck Cancer
Characterization of Central Pain Syndrome in Survivors of Head and Neck Cancer
Sponsor: National Cancer Institute (NCI)
Terminated
Recruitment/accrual impacted by COVID and technical issues with equipment
Other terminated trials from National Cancer Institute (NCI)
Other Head and Neck Cancer trials with similar outcome
This NA trial investigates Head and Neck Cancer and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Sep 2022 — Jul 2024 [monthly]
Terminated NA
-
Apr 2022 — Sep 2022 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2021 — Apr 2022 [monthly]
Recruiting NA
Status: Suspended → Recruiting
▶ Show 6 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Suspended NA
Status: Recruiting → Suspended
-
Feb 2021 — Jun 2021 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .